StackItSmart

Compound reference

Letrozole

Femara

Ancillary compounds1 cited findingClinical review: not reviewed

Pharmacokinetics

Human observational studyAbstract inspected

In a small pharmacokinetic study in postmenopausal breast-cancer patients, letrozole exposure and terminal half-life were greater at steady state than after a single dose (approximately 28% and 42% higher, respectively). A single half-life should not be presented without population and exposure context.[1]

  • Selected postmenopausal oncology population; not male post-AAS recovery data.
  • Abstract-checked; full paper not confirmed open access as of 2026-09-09. No qualified clinical review.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Independent source inspection; applicability narrowed and inherited assertions excluded where unsupported. No qualified clinical review.

· Reopened the abstract on 2026-09-09 (NCBI efetch); verified the exact percentage increases and confidence intervals and added them to the claim text. No correction found.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Narrowly supported passages published with study/product limits; remaining inherited assertions withheld from established-fact displays.

  • Not a comprehensive systematic review. Original monograph topics beyond the individual published claims—including monitoring schedules, contraindication lists, recovery assurances and detailed mechanisms—remain unverified.
  • No qualified clinician has reviewed these claims. Long-term outcomes and all marketed formulations have not been fully assessed.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

  1. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients.

    2001-07. PMID:11745921 · DOI:10.1002/bdd.273 Abstract only.

    Inspected location: PubMed abstract: full Results (half-life and AUC increased 42% [90% CI 1.13-1.78] and 28% [90% CI 1.12-1.47] at steady state vs single dose; ~70% of steady-state dose excreted in urine as parent drug or inactive glucuronide metabolite CGP44645) and Methods (28 patients, two age groups)

    Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts
  • Fresh PubMed EUtils retrieval for inherited lead PMID 11745921; identity, abstract and linked corrections checked where an abstract existed.
  • https://pubmed.ncbi.nlm.nih.gov/11745921/ — abstract; PubMed abstract: Results: single-dose versus steady-state letrozole pharmacokinetics in breast-cancer patients

View this compound in the research library →

Related records in this class

Grouped under Ancillary compounds for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.

StackItSmart

Age confirmation

This reference discusses steroids, SARMs and other compounds. It is educational, not medical advice, and does not recommend using or combining them.

Your confirmation is saved in this browser when storage is available.